



내시경 검사의 합병증

강기주

*Department of Medicine, Samsung Medical Center,
Sungkyunkwan University School of Medicine, Seoul,
Korea*

Major Complications

- Cardiopulmonary complication
- Complications related to sedation
- Bleeding
- Perforation
- Infectious complication

Cardiovascular complication

- Most common
- 40-46% of patients
- Minor changes in vital sign to shock
- Factors leading to oxygen desaturation
 - Age and cardiovascular/pulmonary disease
 - Vasovagal reflex
- Management
 - Resuscitation medication,
 - Reverse agents and equipment

Routine Use of Supplemental Oxygen

- Elderly Patients
 - Relatively decreased baseline arterial oxygen saturation
 - Blunted cardiovascular response to hypercarbia and hypoxia
 - Exaggerated response to opioid-induced respiratory depression
- Abnormal baseline oxygen saturation
- Severe cardiovascular disease
- Desaturation during the examination

Bleeding – Upper endoscopy

Diagnostic endoscopy: 0.15%

Trauma from passing the endoscope

Risk factors:

- Thrombocytopenia: platelet < 20,000 and coagulopathy
- Previous gastric surgery

Mallory-Weiss tears: < 0.1%

Important postprocedural hemorrhage

- Transfusion
- Hospitalization
- Reintervention

Bleeding – Colonoscopy

Diagnostic colonoscopy: 0-0.07%

Biopsy: 0.3%

Polypectomy: 1.5-2%

Immediate postpolypectomy: 1.5%

Delayed postpolypectomy: 1.9%

1-29 days later

Bleeding – Treatment

Indication:
Active bleeding (spurt and oozing) or exposed vessel

Management:
Hemodynamically stable and normal hematocrit
Close monitoring and observation

Endoscopic treatment
Injection
Thermocoagulation
Hemoclip

Angiography
Surgery

Mallory-Weiss syndrome

Bleeding by Biopsy

Hematemesis 4 Hours after EMR

Bleeding risk of endoscopic procedures

Procedure	Risk of bleeding
Low risk of bleeding (<1%)	
Diagnostic endoscopy with or without biopsy	
EGD	0.01–0.13% (22)
Double balloon enteroscopy	0.1% (23)
Colonoscopy	0–0.02% (24,25)
Biliary/pancreatic stent without sphincterotomy	0.26% (26)
Endosonography without FNA	— ^a
Wireless capsule endoscopy	— ^a

Kwok et al, AMJ 2009; 104:3085-3097

Bleeding risk of endoscopic procedures

High risk of bleeding (≥1%)	
Polypectomy	
Gastric	7.2% (27)
Duodenal/ampullary	
1–3 cm	4.5% (28)
>3 cm	10.3% (28)
Colonic	
	0.7–3.3% (24,29,30)
Endoscopic mucosal resection	22% ^a (31)
Biliary sphincterotomy	2.0–3.2% (32,33)
Pneumatic/balloon dilation in achalasia	1.7% ^a (34)
Esophageal stenting	0.5–5.3% (36–38)
PEG placement	2.5% (39)
Endosonography with FNA	1.3–6% ^a (40–42)
Laser ablation and coagulation	1.1% (43)
Variceal sclerotherapy	4–25.4% (44,45)
Variceal band ligation	2.4–5.7% ^a (45,46)
Thermal ablation and coagulation	5% (47)

Kwok et al, AMJ 2009; 104:3085-3097

Conditions associated with a high risk of thromboembolic events

Atrial fibrillation	Previous stroke/transient ischemic attack CHAD ₂ ≥ 3 (see Table 4)
Prosthetic valve	Associated valvular heart disease Discontinuing antiplatelet/anticoagulant in bioprosthetic valve <3 months Mechanical valve in mitral position Mechanical valve with previous thromboembolic event
Coronary disease and stents	Recent acute coronary event <4-6 weeks Discontinuing dual antiplatelet therapy in: Drug-eluting stent <1 year Bare metal stent <1 month
DVT/PE	Discontinuing anticoagulation in event <3 months Recurrent DVT/PE Severe hypercoagulable states, active cancer, paroxysmal nocturnal hemoglobinuria, myeloproliferative syndromes

Kwok et al, AMJ 2009; 104:3085-3097

Recommendations of ASGE

Outlines in procedure risks

- High (Bleeding risk 1-6%)
- Low (Bleeding risk<1%)

Condition risks

- High
- Low → Risk when anticoag. is interrupted 4-7 days estimated at 1 to 2 per 1000 patients (DVT, AF, Biovalves and mech.AVR)

Guideline on the management of anticoagulation and antiplatelet therapy for endoscopic procedures

Gastrointestinal Endoscopy 2002;55:775-9.


Procedure risk	High	Low
High	Discontinue warfarin 3-5 days before procedure. Consider heparin while INR is below therapeutic level.	Discontinue warfarin 3-5 days before procedure. Reinitiate warfarin after procedure.
Low	No change in anticoagulation. Heavier procedures should be delayed while INR is in supratherapeutic range.	

Procedure risk	High-risk procedures	Low-risk procedures
High	<ul style="list-style-type: none"> Polypectomy Biliary sphincterotomy Percutaneous or longer dilation POD placement Endoscopic guided fine needle aspiration Laser ablation and coagulation Treatment of varices 	<ul style="list-style-type: none"> Diagnosis EGD ± biopsy Flex sig ± biopsy Colonoscopy ± biopsy ERCP without sphincterotomy Biliary/pancreatic stent without endoscopic sphincterotomy Endoscopy without fine needle aspiration Enteroscopy

Condition risk	High-risk conditions	Low-risk conditions
High	<ul style="list-style-type: none"> Atrial fibrillation associated with valvular heart disease Mechanical valve in the mitral position Mechanical valve and prior thromboembolic event 	<ul style="list-style-type: none"> Deep vein thrombosis Unoccluded or paroxysmal nonvalvular aortic fibrillation Bioprosthetic valve Mechanical valve in the aortic position

Aspirin and other NSAID use
In the absence of a pre-existing bleeding disorder, endoscopic procedures may be performed in patients taking aspirin or other NSAIDs.

Guidelines for the management of patients on warfarin or clopidogrel undergoing endoscopic procedure



Gut 2008;57:1322-1329




Timing of reinstitution of anticoagulant/antiplatelet therapy after GI endoscopy

Drug	Timing of reinstitution	Grade of recommendation (90)	Special considerations
Warfarin	Same night (1,90)	Grade 1C	Consider recommencing ≥3 days in the case of sphincterotomy (32), gynecological polypectomy, large colonic polypectomy, EMR.
Heparin	2-6h after procedure (1)	N/A	
LMWH	24h after procedure (90)	Grade 1C	Higher risk procedure—48-72h after and lower dose (Grade 1C)
Aspirin/NSAIDs	Next day (90)	Grade 2C	Individualize (2)
Clopidogrel	Next day (2,90)	Grade 2C	Consider delayed reinitiation if higher risk procedure performed

EMR, endoscopic mucosal resection; LMWH, low-molecular-weight heparin; NSAID, nonsteroidal anti-inflammatory drug.

Endoscopy and Anticoagulation

- 내시경 검사 및 치료를 위하여 warfarin이나 anti-platelet 을 중단할 때에는 risk-benefit를 고려해야 한다.
- Antiplatelet를 사용하고 있는 환자에서는 조직검사를 위한 약물중단은 권유되지 않는다.
- 고위험 환자에서 warfarin을 중단할 때에는 heparin을 사용하는 것이 고려되어야 한다.
- 서구에서는 warfarin 사용환자에서, 필요하면 약물중단 없이 내시경 조직검사를 하도록 권하고 있으나, 국내에서는 이에 대한 검토가 필요하다.



Perforation - Upper endoscopy

Diagnostic endoscopy: 0.02-0.2%

Perforation site:

- Distal third of esophagus
- Cervical esophagus: pyriform sinus, Zenker's diverticulum, cricopharyngeal muscle

Predisposing factors

- Presence of anterior cervical osteophytes
- Zenker's diverticulum
- Esophageal stricture
- Malignancy

Perforation - Upper endoscopy

Therapeutic upper endoscopy

- Dilation of benign esophageal stricture
 - Bougie: 0.3-0.4%
 - Caustic strictures: 17%
- Achalasia: 4-6.7%
- Malignant esophageal strictures: -10%
- Gastric outlet obstruction: 0-6.7%

